Comparing Revenue Performance: Bristol-Myers Squibb Company or Arrowhead Pharmaceuticals, Inc.?

Pharma Giants: Revenue Trends from 2014 to 2023

__timestampArrowhead Pharmaceuticals, Inc.Bristol-Myers Squibb Company
Wednesday, January 1, 201417500015879000000
Thursday, January 1, 201538200016560000000
Friday, January 1, 201615833319427000000
Sunday, January 1, 20173140770920776000000
Monday, January 1, 20181614232122561000000
Tuesday, January 1, 201916879557726145000000
Wednesday, January 1, 20208799206642518000000
Friday, January 1, 202113828700046385000000
Saturday, January 1, 202224323100046159000000
Sunday, January 1, 202324073500045006000000
Monday, January 1, 2024355100048300000000
Loading chart...

Cracking the code

A Tale of Two Companies: Revenue Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, revenue performance is a key indicator of success. Over the past decade, Bristol-Myers Squibb Company (BMY) and Arrowhead Pharmaceuticals, Inc. (ARWR) have showcased contrasting revenue trajectories.

Bristol-Myers Squibb, a giant in the industry, consistently reported robust revenues, peaking at approximately $46 billion in 2021. This represents a remarkable 192% increase from 2014. In contrast, Arrowhead Pharmaceuticals, a smaller player, experienced a more volatile journey. Despite starting with modest revenues, Arrowhead saw a significant surge, reaching its highest point in 2022 with a 1,390% increase from 2014.

While Bristol-Myers Squibb's revenue growth reflects stability and market dominance, Arrowhead's trajectory highlights its potential for rapid expansion. However, the data for 2024 remains incomplete, leaving room for speculation on future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025